Alkermes (ALKS) Cash from Investing Activities Growth (5y) (2015 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.34 Bn | 625.58 Bn | 17.26 Bn |
| 2 | AbbVie | 441.84 Bn | 435.27 Bn | 12.70 Bn |
| 3 | Merck | 366.20 Bn | 359.06 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.65 Bn | 258.96 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.41 Bn | 45.03 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 8 | Incyte | 25.52 Bn | 20.98 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.51 Bn | 18.85 Bn | 683.80 Mn |
| 10 | Alkermes | 7.56 Bn | 6.91 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.12% |
| Mar 31, 2026 | -122.92% |
| Dec 31, 2025 | 62.08% |
| Sep 30, 2025 | 3.92% |
| Jun 30, 2025 | -32.19% |
| Mar 31, 2025 | -12.25% |
| Dec 31, 2024 | 32.83% |
| Sep 30, 2024 | -40.43% |
| Jun 30, 2024 | 55.69% |
| Mar 31, 2024 | 9.19% |
| Dec 31, 2023 | -21.88% |
| Sep 30, 2023 | -45.69% |
| Jun 30, 2023 | 30.84% |
| Mar 31, 2023 | 23.51% |
| Dec 31, 2022 | 31.65% |
| Sep 30, 2022 | 21.56% |
| Jun 30, 2022 | -46.43% |
| Mar 31, 2022 | -42.73% |
| Dec 31, 2021 | 48.70% |
| Sep 30, 2021 | -21.75% |